Obermatt
See Similar Stocks →

Intellia Therapeutics

NMQ:NTLA · US45826J1051
BiotechnologySmall

360

25
Profit price23
Owner Earnings Yield1
Dividend Yield1
Price/Sales10
Price/Book10
Return on Capital32
Cash Return on Capital34
Return on Equity34
Profit margins15
Accruals79
Owner Earnings Margin21
Sales growth16
Profit growth4
Reinvestment63
Price momentum78
Debt load57
Refinancing88
Debt Payback1
Liquidity64
Analyst ratings13
Opinion Changes30
Price Target Upside76
Market mood49
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Intellia Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2014
Employees436
Websiteintelliatx.com
ISINUS45826J1051
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
ImmunologyHematologyStem Cell TherapyGeneticsGenetic DisorderOncologyBiotechnologyHealth CareMedical

Description

Intellia Therapeutics, Inc. (Intellia) operates as a biopharmaceutical company focused on revolutionizing medicine by leveraging CRISPR gene editing and other core technologies. Intellia Therapeutics, Inc. applies its proprietary technologies and ex…

Analysis

Middle-of-the-road

Intellia Therapeutics, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is adequate. The company scores 6/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
18
2026

All-time high

18

Jun 2026

All-time low

16

Mar 2026

Average rank

17

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
10
—
—
—
Price/Earnings
67
—
—
—
Price/Book
10
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
12
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Intellia Therapeutics with its peers
Grace Therapeutics
NAQ:GRCE
52
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
AnaptysBio
NSQ:ANAB
44
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
CalciMedica
NAQ:CALC
—
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Fulcrum Therapeutics
NMQ:FULC
24
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Ventyx Biosciences
NSQ:VTYX
51
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Omeros
NMQ:OMER
29
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →